Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: Hematology | Family Medicine
Clinical Trials: Anemia
A listing of clinical trials currently looking for volunteers to enroll in Anemia studies. Click on the closest city to find more detailed information on a research study in your area.
Alabama
Anniston : Research Site
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Birmingham : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Birmingham : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Birmingham : Research Site
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Birmingham : Research Site
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease
View More »
Huntsville : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Huntsville : Research Site
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Mobile : University of South Alabama
Effects of HQK-1001 in Patients With Sickle Cell Disease
Mobile : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Mobile : Research Site
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Montgomery : Research Site
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Arizona
Goodyear : Research Site
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Mesa : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Phoenix : Phoenix Children's Hospital - Ctr for Cancer and Blood Disorders
Effects of HQK-1001 in Patients With Sickle Cell Disease
Phoenix : Research Site
Evaluation of the Conversion From Peginesatide to Epoetin Alfa in Subjects Receiving Hemodialysis
Phoenix : Research Site
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
View More »
Scottsdale : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Tempe : GSK Investigational Site
4 Week Switch Study in Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease
Tempe : Research Site
Evaluation of the Conversion From Peginesatide to Epoetin Alfa in Subjects Receiving Hemodialysis
Tempe :
Ferric Citrate in Managing Serum Phosphorus and Iron Deficiency in Anemic Chronic Kidney Disease (CKD) Subjects Not on Dialysis
Tempe : Research Site
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Tucson : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Arkansas
Fayetteville : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Hot Springs : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Jonesboro : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Little Rock : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Little Rock : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
View More »
Pine Bluff : GSK Investigational Site
4 Week Switch Study in Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease
California
Alhambra : Research Site
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Anaheim : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Azusa : GSK Investigational Site
4 Week Correction Study in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Undergoing Dialysis
Azusa : North America Research Institute
A Phase 2a Study To Evaluate The Pharmacokinetics, Safety, Efficacy, Tolerability, And Pharmacodynamics of Sotatercept (ACE-011) for the Correction of Anemia in Subjects With End-stage Renal Disease on Hemodialysis.
Azusa : Research Site
Evaluation of the Conversion From Peginesatide to Epoetin Alfa in Subjects Receiving Hemodialysis
View More »
Azusa : Research Site
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Chino : GSK Investigational Site
4 Week Correction Study in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Undergoing Dialysis
Chula Vista : Investigational Site
A Study of FG-4592 for the Treatment of Anemia in Chronic Kidney Disease Patients Not Receiving Dialysis
Chula Vista : Research Site
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Costa Mesa : GSK Investigational Site
Assessment of the Pharmacokinetics of GSK1278863 and Metabolites in Normal Subjects and Subjects With Renal Impairment
Culver City : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
East Los Angeles : Research Site
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Fountain Valley : Research Site
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Fresno : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Fullerton : Research Site
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Huntington Beach : Research Site
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Inglewood : Research Site
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
La Jolla : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Phase 1 Study of LY2787106 in Cancer and Anemia
La Jolla : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
La Mesa : California Institute of Renal Research
A Phase 2a Study To Evaluate The Pharmacokinetics, Safety, Efficacy, Tolerability, And Pharmacodynamics of Sotatercept (ACE-011) for the Correction of Anemia in Subjects With End-stage Renal Disease on Hemodialysis.
La Mesa : Research Site
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
La Verne : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Laguna Hills : Research Site
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Lakewood : Research Site
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Lancaster : Research Site
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Los Angeles : GSK Investigational Site
4 Week Correction Study in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Undergoing Dialysis
Los Angeles : GSK Investigational Site
4 Week Switch Study in Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease
Los Angeles : Academic Medical Research Institute
A Phase 2a Study To Evaluate The Pharmacokinetics, Safety, Efficacy, Tolerability, And Pharmacodynamics of Sotatercept (ACE-011) for the Correction of Anemia in Subjects With End-stage Renal Disease on Hemodialysis.
Los Angeles : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Los Angeles : Childrens Hospital Los Angeles
Clinical Importance of Treating Iron Overload in Sickle Cell Disease
Los Angeles : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Los Angeles : Research Site
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Los Angeles : Research Site
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease
Lynwood : GSK Investigational Site
4 Week Switch Study in Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease
Lynwood : Research Site
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Merced : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Modesto : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Monterey Park : Monterery Park Dialysis Center
A Phase 2a Study To Evaluate The Pharmacokinetics, Safety, Efficacy, Tolerability, And Pharmacodynamics of Sotatercept (ACE-011) for the Correction of Anemia in Subjects With End-stage Renal Disease on Hemodialysis.
Northridge : Investigational Site
A Study of FG-4592 for the Treatment of Anemia in Chronic Kidney Disease Patients Not Receiving Dialysis
Northridge : Research Site
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Northridge :
Study of FG-4592 to Correct Anemia in New Dialysis Patients
Oakland : Children's Hospital and Research Center - Oakland
Effects of HQK-1001 in Patients With Sickle Cell Disease
Orange : GSK Investigational Site
4 Week Correction Study in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Undergoing Dialysis
Orange : Nephrology Specialist Medical Group
A Phase 2a Study To Evaluate The Pharmacokinetics, Safety, Efficacy, Tolerability, And Pharmacodynamics of Sotatercept (ACE-011) for the Correction of Anemia in Subjects With End-stage Renal Disease on Hemodialysis.
Oxnard : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Palm Springs : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Redondo Beach : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Redondo Beach : Research Site
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Riverside : GSK Investigational Site
4 Week Correction Study in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Undergoing Dialysis
Riverside : GSK Investigational Site
4 Week Switch Study in Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease
Riverside : Investigational Site
A Study of FG-4592 for the Treatment of Anemia in Chronic Kidney Disease Patients Not Receiving Dialysis
Riverside : Research Site
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Sacramento : Research Site
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
San Diego : Research Site
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease
San Dimas : GSK Investigational Site
4 Week Correction Study in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Undergoing Dialysis
San Dimas : GSK Investigational Site
4 Week Switch Study in Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease
San Francisco : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
San Francisco : Research Site
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease
Santa Monica : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Phase 1 Study of LY2787106 in Cancer and Anemia
Santa Rosa : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Stanford : Stanford University School of Medicine
Pilot Lenalidomide in Adult Diamond-Blackfan Anemia Patients w/ RBC Transfusion-Dependent Anemia
Stanford : Research Site
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease
Tarzana : Lawrence May, MD, Inc.
Red Blood Cell Precursor Formulation to Determine Increased Production
Vallejo : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Walnut Creek : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
West Hills : GSK Investigational Site
4 Week Switch Study in Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease
Westlake Village : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Whittier : American Institute of Research
A Phase 2a Study To Evaluate The Pharmacokinetics, Safety, Efficacy, Tolerability, And Pharmacodynamics of Sotatercept (ACE-011) for the Correction of Anemia in Subjects With End-stage Renal Disease on Hemodialysis.
Whittier : Research Site
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Yuba City : Investigational Site
A Study of FG-4592 for the Treatment of Anemia in Chronic Kidney Disease Patients Not Receiving Dialysis
Yuba City : Research Site
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Yuba City :
Study of FG-4592 to Correct Anemia in New Dialysis Patients
Colorado
Denver : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Denver :
Ferric Citrate in Managing Serum Phosphorus and Iron Deficiency in Anemic Chronic Kidney Disease (CKD) Subjects Not on Dialysis
Westminster : Research Site
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Connecticut
Bridgeport : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Bridgeport : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Middlebury : Research Site
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
North Haven : Research Site
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Orange : Research Site
Evaluation of the Conversion From Peginesatide to Epoetin Alfa in Subjects Receiving Hemodialysis
View More »
Southington : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Waterbury : GSK Investigational Site
4 Week Switch Study in Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease
District of Columbia
Washington : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Washington : Children's National Hospital
Effects of HQK-1001 in Patients With Sickle Cell Disease
Washington : Howard University Hospital
Effects of HQK-1001 in Patients With Sickle Cell Disease
Washington : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Florida
DeLand : Avail Clinical Research, LLC
Iron Deficiency Anemia
View More »
Boynton Beach : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Boynton Beach : Research Site
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Coral Springs : GSK Investigational Site
4 Week Switch Study in Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease
Coral Springs : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Coral Springs : Research Site
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Daytona Beach : GSK Investigational Site
4 Week Correction Study in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Undergoing Dialysis
Daytona Beach : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Daytona Beach : Research Site
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Edgewater : GSK Investigational Site
4 Week Correction Study in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Undergoing Dialysis
Holiday : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Hollywood : Research Site
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Hudson : Research Site
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Jacksonville : GSK Investigational Site
4 Week Correction Study in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Undergoing Dialysis
Jacksonville : Research Site
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Jacksonville Beach : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Jacksonville Beach : Research Site
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Lauderdale Lakes : Research Site
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Lecanto : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Melbourne : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Melbourne : Research Site
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Miami : GSK Investigational Site
4 Week Correction Study in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Undergoing Dialysis
Miami : GSK Investigational Site
4 Week Switch Study in Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease
Miami : GSK Investigational Site
Assessment of the Pharmacokinetics of GSK1278863 and Metabolites in Normal Subjects and Subjects With Renal Impairment
Miami :
Ferric Citrate in Managing Serum Phosphorus and Iron Deficiency in Anemic Chronic Kidney Disease (CKD) Subjects Not on Dialysis
Miami : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Miami : Research Site
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Miami : Research Site
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease
New Port Richey : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
New Port Richey : Research Site
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Ocala :
Ferric Citrate in Managing Serum Phosphorus and Iron Deficiency in Anemic Chronic Kidney Disease (CKD) Subjects Not on Dialysis
Orange City : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Orlando : GSK Investigational Site
Assessment of the Pharmacokinetics of GSK1278863 and Metabolites in Normal Subjects and Subjects With Renal Impairment
Orlando : Research Site
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Orlando : Research Site
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease
Pembroke Pines : GSK Investigational Site
4 Week Correction Study in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Undergoing Dialysis
Pembroke Pines : GSK Investigational Site
4 Week Switch Study in Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease
Pembroke Pines : Research Site
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Port Charlotte : Research Site
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Safety Harbor : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Sarasota : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Tampa : Research Site
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Tampa : H. Lee Moffitt Cancer Center
Study of Sotatercept for the Treatment of Anemia in low-or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) or Non-proliferative Chronic Myelomonocytic Leukemia (CMML)
Titusville : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Georgia
Atlanta : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Phase 1 Study of LY2787106 in Cancer and Anemia
Atlanta : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Atlanta : Research Site
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Augusta : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Augusta : Georgia Health Sciences University
Effects of HQK-1001 in Patients With Sickle Cell Disease
View More »
Augusta : Research Site
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Canton : Research Site
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Covington : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Macon : GSK Investigational Site
4 Week Switch Study in Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease
Macon : Research Site
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Stockbridge : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Thomasville : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Idaho
Meridian : Research Site
Evaluation of the Conversion From Peginesatide to Epoetin Alfa in Subjects Receiving Hemodialysis
Meridian :
Ferric Citrate in Managing Serum Phosphorus and Iron Deficiency in Anemic Chronic Kidney Disease (CKD) Subjects Not on Dialysis
Meridian : Research Site
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Illinois
Centralia : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Chicago : University of Illinois at Chicago
Effects of HQK-1001 in Patients With Sickle Cell Disease
Chicago : Research Site
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Chicago : Research Site
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease
Elk Grove Village : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
View More »
Evanston : GSK Investigational Site
4 Week Correction Study in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Undergoing Dialysis
Galesburg : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Gurnee : GSK Investigational Site
4 Week Switch Study in Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease
Gurnee : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Melrose Park : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Oakbrook Terrace : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Peoria : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Peoria : Research Site
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Quincy : Research Site
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Rockford : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Skokie : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Springfield : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Indiana
Iowa
Ames : Research Site
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Council Bluffs : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Iowa City : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Iowa City : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Iowa City : Research Site
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease
View More »
Sioux City : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Kansas
Hutchinson : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Wichita : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Wichita : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Kentucky
Hazard : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Lexington : University of Kentucky Medical Center
A Phase 2a Study To Evaluate The Pharmacokinetics, Safety, Efficacy, Tolerability, And Pharmacodynamics of Sotatercept (ACE-011) for the Correction of Anemia in Subjects With End-stage Renal Disease on Hemodialysis.
Lexington : Research Site
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Louisville : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Louisville : Research Site
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease
View More »
Mt Sterling : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Paducah : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Louisiana
Alexandria : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Alexandria : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Baton Rouge : Research Site
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Covington : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Lafayette : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
View More »
Lafayette : Research Site
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Marrero : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Metairie : Research Site
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Natchitoches : Research Site
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
New Orleans : Research Site
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease
Ruston : Research Site
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Shreveport : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Shreveport : LSU Health Sciences Center
Effects of HQK-1001 in Patients With Sickle Cell Disease
Shreveport : Research Site
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Slidell : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Maine
Rockport : Research Site
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Maryland
Baltimore : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Baltimore : GSK Investigational Site
Effects of GSK1278863A on Pulmonary Artery Pressure in Healthy Volunteers
Bethesda : US National Institutes of Health - National Heart, Lung, and Blood Institute
A Single Dose Study of the Safety, Blood Levels and Biological Effects of Aes-103 Compared to Placebo in Subjects With Stable Sickle Cell Disease
Bethesda : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Bethesda :
Ferric Citrate in Managing Serum Phosphorus and Iron Deficiency in Anemic Chronic Kidney Disease (CKD) Subjects Not on Dialysis
View More »
Bethesda : Research Site
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Cumberland : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Frederick : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Oxon Hills : Research Site
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Towson : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Massachusetts
Ayer : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Boston : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Boston : Tufts Medical Center
Effects of HQK-1001 in Patients With Sickle Cell Disease
Boston : Brigham and Women's Hospital
Efficacy of Vorinostat to Induce Fetal Hemoglobin in Sickle Cell Disease
Boston : Dana-Farber Cancer Institute
Efficacy of Vorinostat to Induce Fetal Hemoglobin in Sickle Cell Disease
View More »
Boston : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Boston : Research Site
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease
Haverhill : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Lexington : AMAG Pharmaceuticals, Inc.
A Trial of Ferumoxytol for the Episodic Treatment of Iron Deficiency Anemia in Pediatric Subjects With Chronic Kidney Disease
Lexington : AMAG Pharmaceuticals, Inc.
A Trial of Ferumoxytol for the Treatment of Iron Deficiency Anemia in Pediatric Subjects With Dialysis Dependent Chronic Kidney Disease
Lexington : AMAG Pharmaceuticals, Inc.
A Trial of Ferumoxytol for the Treatment of Iron Deficiency Anemia in Pediatric Subjects With Nondialysis-Dependent Chronic Kidney Disease
North Dartmouth : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Plymouth : Research Site
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Springfield : Research Site
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Worcester : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Worcester : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Michigan
Detroit : GSK Investigational Site
4 Week Correction Study in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Undergoing Dialysis
Detroit :
Ferric Citrate in Managing Serum Phosphorus and Iron Deficiency in Anemic Chronic Kidney Disease (CKD) Subjects Not on Dialysis
Detroit : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Detroit :
Study of FG-4592 to Correct Anemia in New Dialysis Patients
Flint : Research Site
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
View More »
Grand Rapids : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Grand Rapids : Research Site
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Midland : Research Site
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Pontiac : Research Site
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Southfield : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Southgate : GSK Investigational Site
4 Week Switch Study in Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease
Minnesota
Duluth : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Minneapolis : GSK Investigational Site
Assessment of the Pharmacokinetics of GSK1278863 and Metabolites in Normal Subjects and Subjects With Renal Impairment
Minneapolis : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Mississippi
Columbus : Research Site
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Gulfport : Research Site
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Jackson : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Tupelo : Fresenius Medical Care North America
A Phase 2a Study To Evaluate The Pharmacokinetics, Safety, Efficacy, Tolerability, And Pharmacodynamics of Sotatercept (ACE-011) for the Correction of Anemia in Subjects With End-stage Renal Disease on Hemodialysis.
Missouri
Jefferson City : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Kansas City : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Kansas City : Research Site
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Kansas City : Research Site
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease
St. Louis : Washington University School of Medicine
A Phase 2a Study To Evaluate The Pharmacokinetics, Safety, Efficacy, Tolerability, And Pharmacodynamics of Sotatercept (ACE-011) for the Correction of Anemia in Subjects With End-stage Renal Disease on Hemodialysis.
View More »
St. Louis : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
St.Louis : Chromalloy American Kidney Center
A Phase 2a Study To Evaluate The Pharmacokinetics, Safety, Efficacy, Tolerability, And Pharmacodynamics of Sotatercept (ACE-011) for the Correction of Anemia in Subjects With End-stage Renal Disease on Hemodialysis.
Montana
Kalispell : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Kalispell : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Nebraska
Grand Island : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Lincoln : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
North Platte : Research Site
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Nevada
Henderson : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Las Vegas : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Las Vegas : Research Site
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
New Hampshire
Lebanon : (851) Dartmouth Hitchcock Medical Center
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Manchester : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
New Jersey
Bayonne : Research Site
Evaluation of the Conversion From Peginesatide to Epoetin Alfa in Subjects Receiving Hemodialysis
Livingston : Research Site
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Livingston : Research Site
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease
Newark : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Sparta : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
View More »
Teaneck : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Vineland : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
New York
Bronx : Einstein-Montefiore Institute for Clinical & Translational Research
The Testosterone Trial - Can testosterone treatment improve unwanted effects of aging in older men?
Jamaica : Biomedical Research Alliance of New York
Anemia - cancer
Jamaica : Biomedical Research Alliance of New York
Anemia- cancer
New Hyde Park : Biomedical Research Alliance of New York
Diamond Blackfan Anemia - Adults
New York : The Rockefeller University Hospital
Entrance into the International Fanconi Anemia Registry (IFAR)
View More »
Albany : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Bronx : The Children's Hospital at Montefiore Medical Center
Effects of HQK-1001 in Patients With Sickle Cell Disease
Bronx : Montefiore Medical Center
Intravenous Gammaglobulin for Sickle Cell Pain Crises
Brooklyn : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Brooklyn : New York Methodist Hospital
Effects of HQK-1001 in Patients With Sickle Cell Disease
Buffalo : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Buffalo : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Buffalo : Research Site
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Cortlandt Manor : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Flushing : Research Site
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Glens Falls : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Goshen : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Great Neck :
Ferric Citrate in Managing Serum Phosphorus and Iron Deficiency in Anemic Chronic Kidney Disease (CKD) Subjects Not on Dialysis
Kingston : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Latham : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
New York : Memorial Sloan Kettering Cancer Center
Accuracy Testing of the Chromosomal Aberration and Gene Mutation Markers of the AMLProfiler
New York : Mount Sinai School of Medicine
Intravenous Gammaglobulin for Sickle Cell Pain Crises
New York : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
New York : Research Site
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease
Nyack : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Orchard Park : Research Site
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Rochester : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Rosedale : Research Site
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Staten Island : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Syracuse : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Valhalla : Research Site
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease
Williamsville : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
North Carolina
Wilmington : Trial Management Associates
Iron Deficiency Anemia - Have you been diagnosed with anemia or have low iron? Do you feel run down or tired all the time?
View More »
Asheboro : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Asheville : GSK Investigational Site
4 Week Correction Study in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Undergoing Dialysis
Asheville :
Ferric Citrate in Managing Serum Phosphorus and Iron Deficiency in Anemic Chronic Kidney Disease (CKD) Subjects Not on Dialysis
Asheville : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Asheville : Research Site
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Burlington : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Chapel Hill : University of North Carolina at Chapel Hill
Effects of HQK-1001 in Patients With Sickle Cell Disease
Chapel Hill : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Charlotte : GSK Investigational Site
4 Week Correction Study in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Undergoing Dialysis
Charlotte : GSK Investigational Site
4 Week Switch Study in Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease
Charlotte : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Concord : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Durham : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Gastronia : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Goldsboro : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Greensboro : Research Site
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Greenville : Research Site
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
High Point : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Huntersville : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Kinston : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Mooresville : Research Site
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Statesville : Research Site
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Washington : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Wilmington : GSK Investigational Site
4 Week Correction Study in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Undergoing Dialysis
Wilmington :
Ferric Citrate in Managing Serum Phosphorus and Iron Deficiency in Anemic Chronic Kidney Disease (CKD) Subjects Not on Dialysis
Winston-Salem : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Phase 1 Study of LY2787106 in Cancer and Anemia
Winston-Salem : Brookview Hills Research Associates, LLC
A Phase 2a Study To Evaluate The Pharmacokinetics, Safety, Efficacy, Tolerability, And Pharmacodynamics of Sotatercept (ACE-011) for the Correction of Anemia in Subjects With End-stage Renal Disease on Hemodialysis.
Winston-Salem : Research Site
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
North Dakota
Bismarck : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Fargo : Research Site
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Ohio
Columbus : Columbus Center for Women's Health Research
Uterine Fibroids and Anemia
View More »
Akron : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Canton : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Cincinnati : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Cincinnati : Research Site
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease
Cleveland : MetroHealth Medical Systems
A Phase 2a Study To Evaluate The Pharmacokinetics, Safety, Efficacy, Tolerability, And Pharmacodynamics of Sotatercept (ACE-011) for the Correction of Anemia in Subjects With End-stage Renal Disease on Hemodialysis.
Cleveland : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Cleveland : Research Site
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease
Columbus : James Cancer Hospital
Accuracy Testing of the Chromosomal Aberration and Gene Mutation Markers of the AMLProfiler
Columbus : Research Site
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease
Garfield Heights : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Marion : Research Site
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Massillon : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Mayfield Heights : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Middletown : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Sandusky : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Oklahoma
Oklahoma City : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Oklahoma City : Research Site
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Tulsa : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Tulsa : Research Site
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Oregon
Portland : GSK Investigational Site
4 Week Correction Study in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Undergoing Dialysis
Portland : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Portland : Research Site
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Portland : Research Site
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease
Roseburg : Research Site
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Pennsylvania
Beaver : Research Site
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Bethlehem : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Bethlehem : Research Site
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Duncansville : Research Site
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Gettysburg : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
View More »
Lancaster : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Norristown : Luitpold Pharmaceuticals, Inc.
Intravenous Ferric Carboxymaltose (FCM) Versus IV Iron Sucrose or IV Iron Dextran in Treating Iron Deficiency Anemia in Women
Philadelphia : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Philadelphia : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Philadelphia : Research Site
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Pittsburgh : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Pittsburgh : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Uniontown : GSK Investigational Site
4 Week Correction Study in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Undergoing Dialysis
Upland : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Willow Grove : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Wynnewood : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
South Carolina
Aiken : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Anderson : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Charleston : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Charleston : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Columbia : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
View More »
Columbia : Research Site
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Greenville : Research Site
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Hilton Head Island : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Orangeburg : Research Site
Evaluation of the Conversion From Peginesatide to Epoetin Alfa in Subjects Receiving Hemodialysis
Orangeburg : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Orangeburg : Research Site
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
South Dakota
Aberdeen : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Sioux Falls : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Watertown : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Tennessee
Dyersburg : Research Site
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Germantown : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Jackson : Research Site
Evaluation of the Conversion From Peginesatide to Epoetin Alfa in Subjects Receiving Hemodialysis
Jackson : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Jackson : Research Site
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
View More »
Kingsport : Research Site
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Knoxville : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Knoxville : Research Site
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Memphis : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Memphis : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Nashville : Nephrology Associates, PC
A Phase 2a Study To Evaluate The Pharmacokinetics, Safety, Efficacy, Tolerability, And Pharmacodynamics of Sotatercept (ACE-011) for the Correction of Anemia in Subjects With End-stage Renal Disease on Hemodialysis.
Tullahoma : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Texas
San Antonio : Sun Research Institute
Have you been diagnosed with anemia or have low iron? Are you experiencing unsatisfactory results from oral iron supplements?
View More »
Abilene : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Amarillo : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Amarillo : Texas Oncology
Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-Match
Arlington : GSK Investigational Site
4 Week Correction Study in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Undergoing Dialysis
Arlington : GSK Investigational Site
4 Week Switch Study in Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease
Arlington : Research Site
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Austin : GSK Investigational Site
4 Week Correction Study in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Undergoing Dialysis
Austin : Research Site
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Beaumont : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Bryan : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Corpus Chisti : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Corpus Christi : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Corsicana : GSK Investigational Site
4 Week Correction Study in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Undergoing Dialysis
Corsicana : Research Site
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Dallas : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Phase 1 Study of LY2787106 in Cancer and Anemia
Dallas : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Dallas : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Fredericksburg : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Garland : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Greenville : GSK Investigational Site
4 Week Correction Study in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Undergoing Dialysis
Greenville : GSK Investigational Site
4 Week Switch Study in Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease
Greenville : Research Site
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Harlingen : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Houston : GSK Investigational Site
4 Week Correction Study in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Undergoing Dialysis
Houston : GSK Investigational Site
4 Week Switch Study in Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease
Houston : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Phase 1 Study of LY2787106 in Cancer and Anemia
Houston : Diagnostic Clinic of Houston
A Phase 2a Study To Evaluate The Pharmacokinetics, Safety, Efficacy, Tolerability, And Pharmacodynamics of Sotatercept (ACE-011) for the Correction of Anemia in Subjects With End-stage Renal Disease on Hemodialysis.
Houston : Innovative Renal Care
A Phase 2a Study To Evaluate The Pharmacokinetics, Safety, Efficacy, Tolerability, And Pharmacodynamics of Sotatercept (ACE-011) for the Correction of Anemia in Subjects With End-stage Renal Disease on Hemodialysis.
Houston : (855) University of Texas, MD Anderson Cancer Center
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Houston : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Houston : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Houston : Research Site
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Houston : Research Site
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease
McAllen : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Mesquite : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Paris : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
San Antonio : GSK Investigational Site
4 Week Correction Study in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Undergoing Dialysis
San Antonio : GSK Investigational Site
4 Week Switch Study in Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease
San Antonio : San Antonio Kidney Disease
A Phase 2a Study To Evaluate The Pharmacokinetics, Safety, Efficacy, Tolerability, And Pharmacodynamics of Sotatercept (ACE-011) for the Correction of Anemia in Subjects With End-stage Renal Disease on Hemodialysis.
San Antonio : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
San Antonio :
Ferric Citrate in Managing Serum Phosphorus and Iron Deficiency in Anemic Chronic Kidney Disease (CKD) Subjects Not on Dialysis
San Antonio : Research Site
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
San Antonio : Research Site
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease
San Antonio : Renal Associates, PA
Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa
Sugar Land : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
The Woodlands : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Phase 1 Study of LY2787106 in Cancer and Anemia
Tyler : Fresenius Medical Care
A Phase 2a Study To Evaluate The Pharmacokinetics, Safety, Efficacy, Tolerability, And Pharmacodynamics of Sotatercept (ACE-011) for the Correction of Anemia in Subjects With End-stage Renal Disease on Hemodialysis.
Tyler : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Waco : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Wichita Falls : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Utah
Ogden : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Vermont
White River Junction : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Virginia
Alexandria : Research Site
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Charlottesville : University of Virginia - Nephrology Clinical Research Center
A Phase 2a Study To Evaluate The Pharmacokinetics, Safety, Efficacy, Tolerability, And Pharmacodynamics of Sotatercept (ACE-011) for the Correction of Anemia in Subjects With End-stage Renal Disease on Hemodialysis.
Charlottesville : Research Site
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease
Fairfax : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Fairfax : Research Site
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
View More »
Hampton : Research Site
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Mechanicsville : Research Site
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Midlothian : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Newport News : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Norfolk : Research Site
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease
Portsmouth : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Richmond : Virginia Commonwealth Univeristy - Center on Health Disparities
Effects of HQK-1001 in Patients With Sickle Cell Disease
Richmond : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Richmond : Research Site
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Roanoke : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Washington
Bremerton : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Burien : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Kirkland : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Seattle : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Seattle : Research Site
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease
View More »
Spokane : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Tacoma : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Tacoma : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Vancouver : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Phase 1 Study of LY2787106 in Cancer and Anemia
Vancouver : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Yakima : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
West Virginia
Bluefield : Research Site
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Wisconsin
Green Bay : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Janesville : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Albania
Tirane :
An Observational Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) in Patients With Chronic Kidney Disease in Pre-Dialysis or Dialysis
Argentina
Adrogue : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Bahia Blanca : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Berazategui : Centro Oncologico de Investigaciones Buenos Aires
Epoetin Alfa (Hemax®) Phase IV Study in Chemotherapy Induced Anemia
Buenos Aires : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Buenos Aires : Centro de Medicina Integral e Investigación Clínica
Epoetin Alfa (Hemax®) Phase IV Study in Chemotherapy Induced Anemia
View More »
Buenos Aires : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Capital Federal : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Cipolletti : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Ciudad Autónoma de Buenos Aires : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Ciudad Autónoma de Buenos Aires : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Ciudad Autonoma de Buenos Aires : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Cordoba : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Corrientes : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
La Plata : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Lanus Este : Hospital Zonal Especializado en Oncología de Lanus
Epoetin Alfa (Hemax®) Phase IV Study in Chemotherapy Induced Anemia
Mar del Plata : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Quilmes : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Quilmes : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Rosario : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Rosario : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
San Miguel de Tucuman : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Santa Fe : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Santa Fe : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Australia
Geelong : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Heidelberg : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Parkville :
A Study of Intravenous Mircera for the Treatment of Anemia in Pediatric Patients on Hemodialysis.
Prahran : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Woolloongabba : (004) Princess Alexandra Hospital
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Austria
Graz : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Graz : University Hospital
Efficacy of NOX-H94 on Anemia of Chronic Disease in Patients With Multiple Myeloma or Lymphoma
Innsbruck : (151) Medizinische Universitat Innsbruck
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Innsbruck : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Innsbruck : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
View More »
Linz : (153) Krankenhaus der Elisabethinen Linz, Interne Abteilung
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Linz : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Salzburg : (154) Universitätsklinik für Innere Medizin Salzburg
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Salzburg : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
St Poelten : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Vienna : AKH Vienna
Efficacy of NOX-H94 on Anemia of Chronic Disease in Patients With Multiple Myeloma or Lymphoma
Vienna : Wilhelminenspital
Efficacy of NOX-H94 on Anemia of Chronic Disease in Patients With Multiple Myeloma or Lymphoma
Wels : (155) Klinikum Wels-Grieskirchen GmbH
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Wels : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Wien : (152) Wiener Gebietskrankenkasse-Hanusch-Krankenhaus
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Wien : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Wien : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Belgium
Aalst : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Aalst : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Antwerpen : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Bonheiden : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Bonheiden : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
View More »
Brasschaat : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Brugge : (203) Algemeen Ziekenhuis Sint-Jan
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Brugge : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Brussel : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Brussels : (206) Cliniques Universitaires Saint Luc
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Charleroi : (205) Grand Hôpital de Charleroi
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Eupen : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Genk : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Gilly : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Hasselt : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Huy : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Ieper : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Leuven : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Liège : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Libramont : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Liege : (201) Centre Hospitalier Universitaire Sart Tilman Liège
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Mechelen : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Namur : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Oostende : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Ottignies : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Roeselare : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Sint-Niklaas : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Turnhout : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Verviers : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Yvoir : (207) Cliniques Universitaires UCL de Mont-Godinne
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Brazil
Belo Horizonte : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Brasilia : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Campinas : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Campo Grande : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Curitba : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
View More »
Curitiba : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Fortaleza : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Fortaleza : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Goiania : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Ijui : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
ItajaÃ- : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Londrina : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Passo Fundo : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Pelotas : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Porto Alegre : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Porto Alegre : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Recife : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Ribeirao Preto : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Riberão Preto : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Rio de Janeiro : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Rio de Janeiro : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
São Paulo : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
São Paulo : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Salvador : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Santo Andre : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Sao Jose dos Campos : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Sao Paulo : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Bulgaria
Haskovo : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Pleven : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Plovdiv : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Plovdiv : University Hospital
Efficacy of NOX-H94 on Anemia of Chronic Disease in Patients With Multiple Myeloma or Lymphoma
Plovdiv : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
View More »
Rouse : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Sofia : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Sofia : Tokuda Hospital
Efficacy of NOX-H94 on Anemia of Chronic Disease in Patients With Multiple Myeloma or Lymphoma
Sofia : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Varna : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Veliko Tarnovo : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Canada
Edmonton : (804) University of Alberta Hospital
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Halifax : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Hamilton : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Mississauga : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Moncton : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
View More »
Montreal : (808) McGill University
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Montreal : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Montreal : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Oshawa : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Ottawa : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Scarborough : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
St. John's : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Toronto : (801) Princess Margaret Hospital
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Toronto : (806) Sunnybrook Odette Cancer Centre
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Toronto : University Health Network Toronto General Hospital
Effects of HQK-1001 in Patients With Sickle Cell Disease
Toronto : The Hospital for Sick Children
Effects of HQK-1001 in Patients With Sickle Cell Disease
Toronto : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Winnipeg : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Chile
San Miguel : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Santiago : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Santiago : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Temuco : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Vina del Mar : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
China
Beijing : Novartis Investigative Site
Safety and Efficacy of Desferasirox in Chinese Patients With Iron Overload and Aplastic Anemia
Beijing : Peking University First Hospital
Study of FG-4592 in Subjects With Chronic Kidney Disease in China
Beijing : Peking University First Hospital
Study of FG-4592 in Subjects With End-Stage Renal Disease Receiving Maintenance Hemodialysis in China
Changsha : 15 Updated
A Double-blind, Double-dummy, Parallel, Active-controlled, Randomized and Multi-center Trial to Investigate Efficacy and Safety in Subjects With Iron Deficiency Anemia for Ferrous (II) Glycine Sulphate Complex Versus Polyferose Capsules Therapy
Chengdu : Sichuan Provincial People's Hospital
Study of FG-4592 in Subjects With Chronic Kidney Disease in China
View More »
Chengdu : West China Hospital
Study of FG-4592 in Subjects With Chronic Kidney Disease in China
DaLian : First affiliated hospital of Dalian medical university
Study of FG-4592 in Subjects With Chronic Kidney Disease in China
Fuzhou : 1 Updated
A Double-blind, Double-dummy, Parallel, Active-controlled, Randomized and Multi-center Trial to Investigate Efficacy and Safety in Subjects With Iron Deficiency Anemia for Ferrous (II) Glycine Sulphate Complex Versus Polyferose Capsules Therapy
Guangzhou : Department of Hematology, Liu Hua Qiao Hospital
Safety and Efficacy Study of Ex Vivo Immunotherapy for Treatment of Aplastic Anemia
Guangzhou : First Affiliated Hospital, Sun Yat-Sen University
Study of FG-4592 in Subjects With Chronic Kidney Disease in China
Guangzhou : First Affiliated Hospital, Sun Yat-Sen University
Study of FG-4592 in Subjects With End-Stage Renal Disease Receiving Maintenance Hemodialysis in China
Hangzhou : 5 Updated
A Double-blind, Double-dummy, Parallel, Active-controlled, Randomized and Multi-center Trial to Investigate Efficacy and Safety in Subjects With Iron Deficiency Anemia for Ferrous (II) Glycine Sulphate Complex Versus Polyferose Capsules Therapy
Hangzhou : Zhejiang University No 1. Hospital
Study of FG-4592 in Subjects With Chronic Kidney Disease in China
Hangzhou : Zhejiang University No 1. Hospital
Study of FG-4592 in Subjects With End-Stage Renal Disease Receiving Maintenance Hemodialysis in China
Jinan : 7 Updated
A Double-blind, Double-dummy, Parallel, Active-controlled, Randomized and Multi-center Trial to Investigate Efficacy and Safety in Subjects With Iron Deficiency Anemia for Ferrous (II) Glycine Sulphate Complex Versus Polyferose Capsules Therapy
Jinan : 8 Updated
A Double-blind, Double-dummy, Parallel, Active-controlled, Randomized and Multi-center Trial to Investigate Efficacy and Safety in Subjects With Iron Deficiency Anemia for Ferrous (II) Glycine Sulphate Complex Versus Polyferose Capsules Therapy
Shanghai : XinHua Hospital
Study of FG-4592 in Subjects With Chronic Kidney Disease in China
Shanghai : Huashan Hospital
Study of FG-4592 in Subjects With Chronic Kidney Disease in China
Shanghai : Renji Hospital
Study of FG-4592 in Subjects With Chronic Kidney Disease in China
Shanghai : RuiJin Hospital
Study of FG-4592 in Subjects With Chronic Kidney Disease in China
Shanghai : RuiJin Hospital
Study of FG-4592 in Subjects With End-Stage Renal Disease Receiving Maintenance Hemodialysis in China
Shanghai : XinHua Hospital
Study of FG-4592 in Subjects With End-Stage Renal Disease Receiving Maintenance Hemodialysis in China
Shanghai : Chang Zheng Hospital
Study of FG-4592 in Subjects With End-Stage Renal Disease Receiving Maintenance Hemodialysis in China
Shanghai : Renji Hospital
Study of FG-4592 in Subjects With End-Stage Renal Disease Receiving Maintenance Hemodialysis in China
Shanxi : 13 Updated
A Double-blind, Double-dummy, Parallel, Active-controlled, Randomized and Multi-center Trial to Investigate Efficacy and Safety in Subjects With Iron Deficiency Anemia for Ferrous (II) Glycine Sulphate Complex Versus Polyferose Capsules Therapy
Shanxi : 14 Updated
A Double-blind, Double-dummy, Parallel, Active-controlled, Randomized and Multi-center Trial to Investigate Efficacy and Safety in Subjects With Iron Deficiency Anemia for Ferrous (II) Glycine Sulphate Complex Versus Polyferose Capsules Therapy
Shenzhen : Shenzhen People's Hospital
Study of FG-4592 in Subjects With Chronic Kidney Disease in China
Shenzhen : ShenZhen People's Hospital
Study of FG-4592 in Subjects With End-Stage Renal Disease Receiving Maintenance Hemodialysis in China
Tianjin : 2 Updated
A Double-blind, Double-dummy, Parallel, Active-controlled, Randomized and Multi-center Trial to Investigate Efficacy and Safety in Subjects With Iron Deficiency Anemia for Ferrous (II) Glycine Sulphate Complex Versus Polyferose Capsules Therapy
Wuxi : 4 Updated
A Double-blind, Double-dummy, Parallel, Active-controlled, Randomized and Multi-center Trial to Investigate Efficacy and Safety in Subjects With Iron Deficiency Anemia for Ferrous (II) Glycine Sulphate Complex Versus Polyferose Capsules Therapy
Xi'an : 9 Updated
A Double-blind, Double-dummy, Parallel, Active-controlled, Randomized and Multi-center Trial to Investigate Efficacy and Safety in Subjects With Iron Deficiency Anemia for Ferrous (II) Glycine Sulphate Complex Versus Polyferose Capsules Therapy
Croatia
Zagreb : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Czech Republic
Benesov : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Benesov u Prahy : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Brno : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Horovice : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Karlovy Vary : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
View More »
Kyjov : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Olomouc : (252) Fakultni nemocnice Olomouc, hemato-onkologicka klinika
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Ostrava-Poruba : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Pardubice : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Praha : (253) Vseobecna Fakultni Nemocnice v Praze
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Praha : (254) Ustav Hematologie a Krevni Transfuze
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Praha 10 : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Praha 4 : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Praha 8 : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Pribram 8 : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Denmark
Frederiksberg : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Glostrup : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Hellerup : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Herlev : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Holbaek : Pharmacosmos
Iron Isomaltoside 1000 (Monofer®) in Non-Dialysis Dependent Chronic Kidney Disease and With Renal-Related Anaemia
View More »
København Ø : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
København S : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Odense : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Roskilde : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Svendborg : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Egypt
Cairo :
A Study of Mircera (C.E.R.A.) in Patients With Pre-Dialysis Chronic Renal Anemia
Cairo : Abu El Reesh Pediatric University Hospital
Effects of HQK-1001 in Patients With Sickle Cell Disease
Cairo : Ain Sham University Hospital
Effects of HQK-1001 in Patients With Sickle Cell Disease
Estonia
Pärnu : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Tallinn : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Finland
Helsinki : Div. of Nephrologia, Helsenky, University Hospital
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO 11)
Jakobstad : Pietarsaari Hospital
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO 11)
Kajaaha : Kainuu Hospital
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO 11)
France
Aix en Provence : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Aix en Provence cedex 01 : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Amiens : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Angers Cedex 9 : (307) Center Hospitalier Universitaire d' Angers
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Bayonne : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
View More »
Besançon Cedex : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Bobigny : (304) Hôpital Avicenne - Service d'Hématologie Clinique
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Bordeaux : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Bourg en Bresse : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Brive la Gaillarde : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Colmar Cedex : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Creteil : Hôpital Henri Mondor
Safety Study of MP4CO in Adult Sickle Cell Patients
Créteil : Henri Mondor University Hospital
Rituximab in Auto-Immune Hemolytic Anemia
Dijon cedex : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Grenoble Cedex 9 : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
La Seyne Sur Mer : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
La Tronche : (303) Hopital A. Michallon
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Le Mans Cedex 9 : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Lille :
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO 11)
Lille Cedex : (305) Hôpital Claude Hurlezk service des maladies du sang
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Lille Cedex : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Longjumeau cedex 1 : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Marseille : (306) Institut Paoli Calmettes Centre Regional de Lutte Contre le Cancer
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Marseille : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Mont de Marsan : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Montpellier cedex 05 : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Nancy : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Orléans : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Périgueux cedex : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Paris : Research Facility
Efficacy and Safety of Peginesatide in the Treatment of Anemia in Patients With Chronic Kidney Disease
Paris : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Paris Cedex 14 : (302) Groupe hospitalier Cochin Saint-Vincent de Paul
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Paris Cedex 20 : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Pessac Cedex : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Poitiers : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Pontoise Cedex : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Pontoise Cedex : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Pringy Cedex : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Reims : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Reims Cedex : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Rouen : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Saint Grégoire cedex : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Saint Herblain : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Saint Quentin : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Soissons :
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO 11)
Soissons Cedex : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Soyaux : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Strasbourg : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Suresnes :
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO 11)
Toulouse Cedex 09 : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Vichy cedex : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Villefranche Sur Saone Cedex : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Germany
Alsfeld :
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO 11)
Alzey :
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO 11)
Augsburg : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Bad Berka : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Bad Nauheim :
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO 11)
View More »
Bad Wildungen :
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO 11)
Bamberg : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Bayreuth :
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO 11)
Berlin : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Berlin : MediOnko-Institut GRR
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Berlin : "Medizinisches Versorgungszentrum
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Berlin : Fachärzte für Innere Medizin - Hämatologie u. Internistische Onkologie
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Berlin : Onkoplan GmbH/ Onkologische Schwerpunktpraxis
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Berlin :
Combined Single / Multiple Dose Escalation Study in Patients With Renal Anemia Due to CKD (Chronic Kidney Disease)
Berlin : Vivantes Klinikum Neukölln, Klinikum für Geburtsmedizin
Comparative Efficacy and Safety of Intravenous Ferric Carboxymaltose (FCM) Versus Oral Iron for Iron Deficiency Anaemia in Pregnant Women
Berlin :
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO 11)
Berlin : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Bonn : "Praxiskooperation Bonn-Euskirchen
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Borken : "Facharzt für Innere Medizin
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Brandenburg : Frauenarzt
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Bremerhaven : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Chemnitz : Poliklinik GmbH Chemnitz
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Cottbus : Fachärztin für Innere Medizin / Hämatologie / Onkologie
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Darmstadt :
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO 11)
Dresden : (359) Gemeinschaftspraxis fur Hamatologie un Onkologie
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Dresden : "Facharzt für Innere Medizin/
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Dresden : Univesitätsklinikum Carl Gustav Carus
Ferric Carboxymaltose in Type 2 Diabetes Mellitus (T2DM) Patients on Oral Antidiabetic Medication
Duisburg : (352) Sankt Johannes Hospital Duisburg
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Düsseldorf : (356) Universitätsklinikum Düsseldorf, Klinik für Hämatologie, Onkologie und Klinische Immunologie
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Eisenach : "Facharzt für Innere Medizin Hamatologie und Internistische Onkologie
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Erlangen : Research Facility
Efficacy and Safety of Peginesatide in the Treatment of Anemia in Patients With Chronic Kidney Disease
Essen :
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO 11)
Frankenthal : Internist / Hämatologe / Intern. Onkologie
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Frankfurt : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Garbsen : Internist - Hämatologe - Onkologe
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Georgsmarienhütte : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Gosiar : Hämatologie und Onkologie
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Goslar : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Groitzsch : Medizinisches Studien- und Dokumentationszentrum
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Gutersloh :
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO 11)
Hagenow :
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO 11)
Halberstadt : FA für Innere Medizin - Hämatologie - Internistische Onkologie
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Halle/ Saale : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Halle/Saale : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Hamburg :
A Study of Intravenous Mircera for the Treatment of Anemia in Pediatric Patients on Hemodialysis.
Hamburg : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Hamm :
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO 11)
Hannover : (354) Medizinische Hochschutle Hannover
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Hannover : Internist - Hämatologe - Onkologe
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Hannover : MediProjekt Ges. f. Medizinstatistik und Projektentwicklung
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Hannover :
Combined Single / Multiple Dose Escalation Study in Patients With Renal Anemia Due to CKD (Chronic Kidney Disease)
Heidelberg : (357) Universitat Heidelberg
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Heidenheim : ODZ-Petersen GmbH
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Hemer : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Herne : DOKUSAN Gesellschaft für medizinische Studien mbH & Co. KG
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Herne :
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO 11)
Herzberg :
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO 11)
Homberg :
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO 11)
Hurth-Hermulheim :
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO 11)
Ingelheim : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Jena : "Medizinisches Versorgungszentrum MP Saaletal GmbH
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Köln : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Köln : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Kaiserslautern :
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO 11)
Kassel : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Kiel :
Combined Single / Multiple Dose Escalation Study in Patients With Renal Anemia Due to CKD (Chronic Kidney Disease)
Koln :
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO 11)
Köln :
Combined Single / Multiple Dose Escalation Study in Patients With Renal Anemia Due to CKD (Chronic Kidney Disease)
Krefeld : OnkoMed GbR
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Leipzig : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Leverkusen :
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO 11)
Ludwigslust :
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO 11)
Luebeck :
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO 11)
München : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Magdeburg :
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO 11)
Mainz : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Mannheim : (353) Universitatsklinikum Mannheim
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Mannheim : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Marburg : Klinik Für Frauenheilkunde und Geburtshilfe Universitätsklinikum Marburg
Comparative Efficacy and Safety of Intravenous Ferric Carboxymaltose (FCM) Versus Oral Iron for Iron Deficiency Anaemia in Pregnant Women
Marburg : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Mayen :
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO 11)
Mettmann :
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO 11)
Moers : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Muenster : University Hospital Muenster
Intravenous Ferric Carboxymaltose (Ferinject) in Patients Undergoing Orthopaedic Surgery
Munchen : (355) Klinikum rechts der Isar, Technische Universitat Munchen
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Munchen : Facharzte fur Innere Medizin - Hamatologie u. Intermistische Onkologie - Bluttransfusionswesen
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Munchen : Facharzle fur Innere Medizin - Hamatologie u. Intemistische Onkologie
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Munchen :
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO 11)
München :
Combined Single / Multiple Dose Escalation Study in Patients With Renal Anemia Due to CKD (Chronic Kidney Disease)
München : Perinatalzentrum, Klinikum Innenstadt LMU
Comparative Efficacy and Safety of Intravenous Ferric Carboxymaltose (FCM) Versus Oral Iron for Iron Deficiency Anaemia in Pregnant Women
Munster : Gemeinschaftspraxis für Hämatologie und Onkologie
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Nürnberg : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Neunkirchen : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Neuss : Tumorzentrum Niederrhein GmbH
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Oberhausen : Überörtliche Gemeinschaftspraxis
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Oberhausen : Facharzt für Frauenheilkunde und Geburtshilfe
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Olpe : Medizinisches Versorgungszentrum Onkologische Schwerpunktpraxis
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Oranienburg : Fachärztin für Frauenheilkunde und Geburtshilfe
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Osnabruck : Paracelsusklinik
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Paradiese : Medizinisches Versorgungszentrum GbR
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Parchim : FA f. Innere Medizin, Onkologie und Endokrinologie
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Parchim : Frauenarzt
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Plauen : FA für Innere Medizin
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Potsdam :
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO 11)
Quedlinburg :
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO 11)
Remscheid : Facharzt für Innere Medizin - Medikamentöse Tumortheraphie
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Rodgau : Frauenarzt
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Rotenburg (Wümme) : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Saarlouis :
An Observational Study of Mircera (Methoxy Polyethylene Glycol-epoetin Beta) in Patients With Renal Anemia
Saarlouis :
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO 11)
Schoenebeck : FA fur Innere Medizin - Hamatologie - Intermistische Onkologie
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Schwedt : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Soest : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Solingen :
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO 11)
Stralsund : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Stralsund : "FA f. Frauenheilkunde und Geburtshilfe SP Gynakologische Onkologie
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Stuttgart : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Ulm : University Hospital Ulm
Accuracy Testing of the Chromosomal Aberration and Gene Mutation Markers of the AMLProfiler
Ulm : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Velbert : Praxis fur Hamatologie und Internistische Onkologie
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Verden : Facharzt für Innere Medizin Hamatologie und Onkologie
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Viersen : Dr. med. Sven Herrnberger
MONITOR-CKD5 - Multi-level Evaluation of Anaemia Treatment, Outcomes, and Determinants in Chronic Kidney Disease Stage 5
VS-Villingen : Onkologische Schwerpunktpraxis Hamatologie und Onkologie
Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
Würselen : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Weisbaden :
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO 11)
Wuppertal :
Combined Single / Multiple Dose Escalation Study in Patients With Renal Anemia Due to CKD (Chronic Kidney Disease)
Greece
Athens : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Chania : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Larissa : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Piraeus : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Thessaloniki : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Hong Kong
Hong Kong : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Hong Kong : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Hong Kong :
Study of FG-4592 to Correct Anemia in New Dialysis Patients
Kowloon : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
New Territories : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
View More »
New Territories : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
India
Ahmedabad :
A Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) for the Treatment of Chronic Renal Anaemia in Patients With Diabetic Nephropathy
Ahmedabad :
An Observational Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) in Chronic Kidney Disease Patients on Dialysis With Renal Anemia
Ahmedabad : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Ahmednagar : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Aurangabad : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
View More »
Bangalore : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Bhubaneswar :
An Observational Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) in Stage III-IV Chronic Kidney Disease Patients Not on Dialysis With Renal Anemia
Bikaner : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Chennai : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Coimbatore : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Delhi :
A Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) for the Treatment of Chronic Renal Anaemia in Patients With Diabetic Nephropathy
Gurgaon : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Hyderabad :
A Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) for the Treatment of Chronic Renal Anaemia in Patients With Diabetic Nephropathy
Hyderabad :
An Observational Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) in Stage III-IV Chronic Kidney Disease Patients Not on Dialysis With Renal Anemia
Hyderabad : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Hyderabad : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Jaipur : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Kochi : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Kolkata :
A Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) for the Treatment of Chronic Renal Anaemia in Patients With Diabetic Nephropathy
Kolkata :
An Observational Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) in Chronic Kidney Disease Patients on Dialysis With Renal Anemia
Kolkata : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Lucknow : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Ludhiana : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Mangalore : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Miraj : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Mumbai :
A Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) for the Treatment of Chronic Renal Anaemia in Patients With Diabetic Nephropathy
Mumbai :
An Observational Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) in Stage III-IV Chronic Kidney Disease Patients Not on Dialysis With Renal Anemia
Mumbai : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Mumbai : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Nagpur : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Nashik : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Nashik : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
New Delhi : Apollo Hospitals
A Study of Intravenous Iron Isomaltoside 1000 (Monofer®) as Mono Therapy (Without Erythropoeisis Stimulating Agents) in Comparison With Oral Iron Sulfate in Subjects With Non-myeloid Malignancies Associated With Chemotherapy Induced Anaemia (CIA)
New Delhi :
A Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) for the Treatment of Chronic Renal Anaemia in Patients With Diabetic Nephropathy
New Delhi :
An Observational Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) in Chronic Kidney Disease Patients on Dialysis With Renal Anemia
New Delhi : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
New Delhi : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Pune :
A Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) for the Treatment of Chronic Renal Anaemia in Patients With Diabetic Nephropathy
Pune :
An Observational Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) in Chronic Kidney Disease Patients on Dialysis With Renal Anemia
Pune : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Pune : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Vadodara :
An Observational Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) in Stage III-IV Chronic Kidney Disease Patients Not on Dialysis With Renal Anemia
Vellore :
An Observational Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) in Stage III-IV Chronic Kidney Disease Patients Not on Dialysis With Renal Anemia
Ireland
Dublin : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Galway :
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO 11)
Israel
Askelon : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Beer Sheva : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Givatayim : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Hadera : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Haifa : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
View More »
Holon : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Jerusalem : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Jerusalem : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Jerusalem : Hadassah Medical Organization
Safety and Efficacy of Sustained Erythropoietin Therapy
Kfar Saba : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Kfar Saba : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Petach Tikva : (404) Rabin Medical Center
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Poria Eylit : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Rehovot : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Safed : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Tel Aviv : (401) Tel Aviv Sourasky Medical Center
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Tel Aviv : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Tel Aviv : Tel Aviv Sourasky Medical Center
Safety and Efficacy of Sustained Erythropoietin Therapy
Tel Hashomer : (402) Chaim Sheba Medical Center
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Italy
Alessandria : (456) Azienda Ospedaliera SS. Antonio E. Biagio E. Cesare Arrigo di Allessandria
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Ancona : U.O. Nefrologia e Dialisi, Azienda Ospeadaliero-Universitaria Ospedali Riuniti
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO 11)
Anzio : Ospedali Riuniti Anzio-Nettuno, Nefrologia e dialisi ASL RMH
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO 11)
Bergamo : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Bologna : (460) Instituto Di Ematologia ED Oncologia Medica "LA Seragnoli" Policlinico S. Orsola Malpighi
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
View More »
Cagliari : (461) Ospedale R. Binaghi
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Cagliari : (457) Azienda Ospedaliero-Universitaria di Cagliari
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Catania : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Catania : Azienda ospedialiera per l'Emergenza Cannizzaro - Divisione di Nefrologia, Dialisi e Trapianto
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO 11)
Cefalù PA : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Cesenatico (FC) : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Chieri : TO 5 - SC Nefrologia 3 Dialisi
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO 11)
Cortona AR : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Eboli : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Faenza RA : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Ferrara : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Firenze : (462) Azienda Ospedalieo - Universitaria Careggi
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Forlì : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Lecce : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Lugo RA : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Meldola FC : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Messina : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Milano : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Milano : Ospadle Niguarda Ca Granda - U.O. Nefrologia e Dialisi e Terapi Medica del Trapianto Renale
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO 11)
Naples : (458) AORN A. Cardarelli
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Naples : Dipartimento do Patologia Sistematica
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO 11)
Napoli : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Napoli : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Napoli : Azienda Ospedaliera di Rilievo Nazionale Antonio Cardarelli - U.O. S.C. Nefrologia ed Emodialisi
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO 11)
Napoli : Dialysis
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO 11)
Nocera : ASL SA 1 P.O. Umberto 1 - U.O.C. di Nefrologia e Dialisi
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO 11)
Nola : Ospedale Santa maria Della Pieta U.O.C. di Nefrologia e Dialisi
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO 11)
Padova : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Palermo : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Pavia : Lavoro e Delia Riabilitazione, Divisione Nefrologia ed Emodialisi
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO 11)
Ravenna : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Rionero in Vulture : (455) IRCCS Centro di Riferimento Oncologico di Basilicata di Rionero in Vulture
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Roma : (452) Azienda Ospedaliera Universitaria Policlinico Tor Vergata
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Roma : (463) Universita Cattolica Sacro Cuore
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Roma : (453) Azienda Policlinico Umberto l di Roma
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Roma : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Roma : Fondazinoe PTV Ploiclinico Tor Vergata U.O.S.D. Nefrologia e Dialisi
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO 11)
Roma : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
S. Angelo dei Lombardi : Dialisi
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO 11)
San Giovanni Rotondo FG : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Santa Maria : Presidio Ospedaliero S. Guiseppe e Melorio ausl CE/2 S-U.O. Nefrologia e Dialisi
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO 11)
Soverato : Presidio Ospedaliero de Soverato Servizio Dialisi
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO 11)
Torino : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Torino : Complessa Nefrologia e Dialisi
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO 11)
Torino : OSPEDALE MARTINI - SC, Nefrologia e Dialisi
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO 11)
Udine : (451) Azienda Ospedaliero Universitaria "S. Maria della Misericordia" di Udine
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Udine : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Zingonia-Oslo Sotto : Bergamaschi, U.O. Nefrologia e Dialisi
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO 11)
Japan
Fukuoka : Novartis Investigative Site
Efficacy and Safety of Deferasirox in Patients With Chronic Anemia and Transfusional Hemosiderosis
Hiroshima : (908) Hiroshima University Hospital
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Hiroshima : Novartis Investigative Site
Efficacy and Safety of Deferasirox in Patients With Chronic Anemia and Transfusional Hemosiderosis
Hyogo : Novartis Investigative Site
Efficacy and Safety of Deferasirox in Patients With Chronic Anemia and Transfusional Hemosiderosis
Isehara : (904) Tokai University School of Medicine
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
View More »
Ishikawa : Novartis Investigative Site
Efficacy and Safety of Deferasirox in Patients With Chronic Anemia and Transfusional Hemosiderosis
Kamogawa : (910) Kameda General Hospital
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Kumamoto : Novartis Investigative Site
Efficacy and Safety of Deferasirox in Patients With Chronic Anemia and Transfusional Hemosiderosis
Kyoto : Novartis Investigative Site
Efficacy and Safety of Deferasirox in Patients With Chronic Anemia and Transfusional Hemosiderosis
Nagasaki : (909) Nagasaki University Hospital
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Nagasaki : Novartis Investigative Site
Efficacy and Safety of Deferasirox in Patients With Chronic Anemia and Transfusional Hemosiderosis
Nagoya : (906) National Hospital Organization Nagoya Medical Center
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Nagoya : Novartis Investigative Site
Efficacy and Safety of Deferasirox in Patients With Chronic Anemia and Transfusional Hemosiderosis
Osaka : (907) Osaka Red Cross Hospital
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Osaka : Novartis Investigative Site
Efficacy and Safety of Deferasirox in Patients With Chronic Anemia and Transfusional Hemosiderosis
Sapporo : Novartis Investigative Site
Efficacy and Safety of Deferasirox in Patients With Chronic Anemia and Transfusional Hemosiderosis
Sendai : (911) Tohoku University Hospital
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Shibuya : (902) Japanese Red Cross Medical Center
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Shimotsuga-gun : Novartis Investigative Site
Efficacy and Safety of Deferasirox in Patients With Chronic Anemia and Transfusional Hemosiderosis
Shimotsuke : (901) Jichi Medical University Hospital
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Shinagawa : (903) Kanto Medical Center NTT EC
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Tochigi : Novartis Investigative Site
Efficacy and Safety of Deferasirox in Patients With Chronic Anemia and Transfusional Hemosiderosis
Tokyo : Novartis Investigative Site
Efficacy and Safety of Deferasirox in Patients With Chronic Anemia and Transfusional Hemosiderosis
Toyama : Novartis Investigative Site
Efficacy and Safety of Deferasirox in Patients With Chronic Anemia and Transfusional Hemosiderosis
Korea, Republic of
Daegu : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Gwangju : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Seoul : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Latvia
Daugavpils : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Riga : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Lebanon
Beirut : American University of Beirut Medical Center
Effects of HQK-1001 in Patients With Sickle Cell Disease
Beirut : Rafik Hariri University Hospital
Effects of HQK-1001 in Patients With Sickle Cell Disease
Beirut : Chronic Care Center
Effects of HQK-1001 in Patients With Sickle Cell Disease
Lithuania
Alytus : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Kaunas : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Siauliai : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Vilnius : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Vilnius : Research Site
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease
Luxembourg
Differdange : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Luxembourg : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Macedonia, The Former Yugoslav Republic of
Strumica :
An Observational Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) as Maintenance Treatment in Patients With Chronic Renal Anemia on Haemodialysis
Malaysia
Kota Bharu : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Kota Kinabalu : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Kuala Lumpur : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Kuantan : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Mexico
Aguascalientes :
A Study of The Effect of Altitude on Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) Dose Requirements in Patients With Chronic Renal Anemia in Pre-Dialysis or Dialysis
Aguascalientes : Research Site
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease
Colima : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Distrito Federal :
A Study of The Effect of Altitude on Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) Dose Requirements in Patients With Chronic Renal Anemia in Pre-Dialysis or Dialysis
Distrito Federal : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
View More »
Guadajalara : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Guadalajara : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Guadalajara : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Merida : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Merida : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Mexicali :
A Study of The Effect of Altitude on Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) Dose Requirements in Patients With Chronic Renal Anemia in Pre-Dialysis or Dialysis
Mexico : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Mexico : Research Site
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease
Mexico City : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Mexico City : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Monterrey : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Morelia :
A Study of The Effect of Altitude on Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) Dose Requirements in Patients With Chronic Renal Anemia in Pre-Dialysis or Dialysis
Oaxaca : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Puebla : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Pureto Vallarta :
A Study of The Effect of Altitude on Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) Dose Requirements in Patients With Chronic Renal Anemia in Pre-Dialysis or Dialysis
Queretaro : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Saltillo : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
San Luis Potosi : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Veracruz :
A Study of The Effect of Altitude on Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) Dose Requirements in Patients With Chronic Renal Anemia in Pre-Dialysis or Dialysis
Xalapa : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Montenegro
Podgorica :
An Observational Study of Mircera in Patients With Chronic Renal Anemia on Dialysis (CKD Stage V) or Not on Dialysis (CKD Stage III-IV)
Netherlands
Almelo : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Amstelveen : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Arnhem : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Breda : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Breda : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
View More »
Delft : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Den Haag : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Deventer : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Dordrecht : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Enschede : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Groningen : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Haarlem : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Harderwijk : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Heerlen : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Hoorn : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Leiderdorp : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Purmerend : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Roosendaal : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Rotterdam : Erasmus Medical Center
Accuracy Testing of the Chromosomal Aberration and Gene Mutation Markers of the AMLProfiler
Rotterdam : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Rotterdam : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Vlissingen : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Zutphen : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Norway
Ã…lesund : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Arendal : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Oslo : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Skien : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Stavanger : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Pakistan
Lahore :
An Observational Study of Mircera (Methoxy Polyethylene Glycol-epoetin Beta) in Anemic Patients With Chronic Kidney Disease (NORM)
Philippines
Baguio City : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Cebu City : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Davao City : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Makati City : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Manila : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
View More »
Metro Manila : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Pasig City, MetroManila : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Quezon City : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Taguig City : FNRI
Nutrient Fortified Oat Drink
Poland
Bartoszyce :
An Observational Study of Mircera in Renal Anemia Correction In Dialysed Patients During Daily Clinical Practice
Bialystok : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Bialystok : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Bydgoszcz :
An Observational Study of Mircera in Renal Anemia Correction In Dialysed Patients During Daily Clinical Practice
Bydgoszcz : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
View More »
Ciechanow :
An Observational Study of Mircera in Renal Anemia Correction In Dialysed Patients During Daily Clinical Practice
Czestochowa :
An Observational Study of Mircera in Renal Anemia Correction In Dialysed Patients During Daily Clinical Practice
Debica :
An Observational Study of Mircera in Renal Anemia Correction In Dialysed Patients During Daily Clinical Practice
Gdansk :
A Study of Intravenous Mircera for the Treatment of Anemia in Pediatric Patients on Hemodialysis.
Gdansk : (504) Katedra I Klinika Hematologii z Osrodkiem Transplantacji Szpiku Kostnego AM; SPSK nr 1
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Gdansk : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Gdansk : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Gdansk : Research Site
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease
Gdynia : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Gliwice :
An Observational Study of Mircera in Renal Anemia Correction In Dialysed Patients During Daily Clinical Practice
Glucholazy : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Gorzow Wielkopolski :
An Observational Study of Mircera in Renal Anemia Correction In Dialysed Patients During Daily Clinical Practice
Grudziadz :
An Observational Study of Mircera in Renal Anemia Correction In Dialysed Patients During Daily Clinical Practice
Hajnowka :
An Observational Study of Mircera in Renal Anemia Correction In Dialysed Patients During Daily Clinical Practice
Kepno :
An Observational Study of Mircera in Renal Anemia Correction In Dialysed Patients During Daily Clinical Practice
Konin :
An Observational Study of Mircera in Renal Anemia Correction In Dialysed Patients During Daily Clinical Practice
Koszalin : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Krakow : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Krakow : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Krakow : Novartis Investigative Site
Efficacy and Safety of Deferasirox in Patients With Chronic Anemia and Transfusional Hemosiderosis
Krakow : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Lodz :
A Study of Intravenous Mircera for the Treatment of Anemia in Pediatric Patients on Hemodialysis.
Lodz :
An Observational Study of Mircera in Renal Anemia Correction In Dialysed Patients During Daily Clinical Practice
Lodz : Research Site
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease
Lomza : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Lubin : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Lublin :
A Study of Intravenous Mircera for the Treatment of Anemia in Pediatric Patients on Hemodialysis.
Lublin : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Milicz :
An Observational Study of Mircera in Renal Anemia Correction In Dialysed Patients During Daily Clinical Practice
Olsztyn : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Olsztyn : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Pila :
An Observational Study of Mircera in Renal Anemia Correction In Dialysed Patients During Daily Clinical Practice
Polanica Zdroj :
An Observational Study of Mircera in Renal Anemia Correction In Dialysed Patients During Daily Clinical Practice
Poznan : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Radom :
An Observational Study of Mircera in Renal Anemia Correction In Dialysed Patients During Daily Clinical Practice
Rybnik :
An Observational Study of Mircera in Renal Anemia Correction In Dialysed Patients During Daily Clinical Practice
Rzeszow :
An Observational Study of Mircera in Renal Anemia Correction In Dialysed Patients During Daily Clinical Practice
Sandomierz :
An Observational Study of Mircera in Renal Anemia Correction In Dialysed Patients During Daily Clinical Practice
Siedlce :
An Observational Study of Mircera in Renal Anemia Correction In Dialysed Patients During Daily Clinical Practice
Slupsk :
An Observational Study of Mircera in Renal Anemia Correction In Dialysed Patients During Daily Clinical Practice
Stalowa Wola : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Starachowice :
An Observational Study of Mircera in Renal Anemia Correction In Dialysed Patients During Daily Clinical Practice
Suwalki :
An Observational Study of Mircera in Renal Anemia Correction In Dialysed Patients During Daily Clinical Practice
Suwalki : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Szczecin : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Walbrzych : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Warsaw : (503) Instytut Hematologii i Tansfuzjologii, Klinika Hematologii
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Warszawa :
An Observational Study of Mircera in Renal Anemia Correction In Dialysed Patients During Daily Clinical Practice
Warszawa : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Warszawa : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Warszawa : Novartis Investigative Site
Efficacy and Safety of Deferasirox in Patients With Chronic Anemia and Transfusional Hemosiderosis
Warszawa : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Wolomin :
An Observational Study of Mircera in Renal Anemia Correction In Dialysed Patients During Daily Clinical Practice
Wroclaw :
An Observational Study of Mircera in Renal Anemia Correction In Dialysed Patients During Daily Clinical Practice
Wroclaw : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Wroclaw : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Wroclaw : Novartis Investigative Site
Efficacy and Safety of Deferasirox in Patients With Chronic Anemia and Transfusional Hemosiderosis
Wroclaw : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Zabrze : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Zgorzelec :
An Observational Study of Mircera in Renal Anemia Correction In Dialysed Patients During Daily Clinical Practice
Zielona Gora : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Portugal
Canelas : Caledial
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO 11)
Coimbra : (553) Hospitais da Universidade de Coimbra
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Coimbra : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Faro : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Lisboa : (552) Instituto Português de Oncologia de Lisboa de Francisco Gentil, EPE
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
View More »
Lisboa : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Puerto Rico
Caguas : Research Site
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Ponce : Research Site
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
San Juan : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
San Juan : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
San Juan : Research Site
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Romania
Alba Iulia : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Arad : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Bacau : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Baia-Mare : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Brasov : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
View More »
Brasov : Spitalul Judetean
Efficacy of NOX-H94 on Anemia of Chronic Disease in Patients With Multiple Myeloma or Lymphoma
Brasov : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Bucharest : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Bucuresti : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Bucuresti : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Cluj Napoca : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Cluj-Napoca : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Cluj-Napoca : Institutul Oncologic
Efficacy of NOX-H94 on Anemia of Chronic Disease in Patients With Multiple Myeloma or Lymphoma
Craiova : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Lasi : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Oradea : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Oradea : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Ramnicu Valcea : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Suceava : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Targu Mures : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Targu Mures : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Timisoara : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Timisoara : Research Site
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Timisoara : Oncomed
Efficacy of NOX-H94 on Anemia of Chronic Disease in Patients With Multiple Myeloma or Lymphoma
Russian Federation
Arkhangelsk : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Ivanovo : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Kirov : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Krasnodar : Research Site
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease
Kursk : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
View More »
Moscow : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Moscow : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Moscow :
Study of FG-4592 to Correct Anemia in New Dialysis Patients
Moscow : Research Site
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease
Novosibirsk : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Obninsk : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Orenburg : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Penza : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Saint Petersburg : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Saint Petersburg : Research Site
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease
Sankt-Petersburg : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Saratov : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
St Petersburg : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
St Petersburg : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
St. Petersburg : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Stavropol' : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Ufa : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Volgograd : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Voronezh : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Yaroslavl : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Serbia
Belgrade : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Gornji Matejevac : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Kragujevac : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Sremska Kamenica : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Singapore
Singapore : Novartis Investigative Site
Efficacy and Safety of Deferasirox in Patients With Chronic Anemia and Transfusional Hemosiderosis
Slovakia
Banska Bystrica : Research Site
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease
Bardejov : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Bratislava : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Bratislava : Research Site
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease
Kosice : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
View More »
Kosice : Research Site
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease
Lucenec : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Nitra : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Presov : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Slovenia
Golnik : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Pohorje : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
South Africa
Bloemfontein : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Boksburg : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Cape Town : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Durban : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Durban : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
View More »
Johannesburg : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Johannesburg : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Overport : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Parow : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Polokwane : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Pretoria : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Somerset West : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Soweto : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Worcester : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Spain
Alicante : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Alicante : Universitario de Alicante
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO 11)
Badalona : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Barcelona : (607) Hospital Clinic i Provincial - Servicio de Hematologia y Hemoterapia
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Barcelona : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
View More »
Barcelona : Hospital de Barcelona
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO 11)
Barcelona : Fundacio Puigvert
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO 11)
Barcelona : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Benalmadena : Xanit Hospital Internacional
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO 11)
Benidorm : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
El Palmar : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Fuenlabrada : Fuenlabrada
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO 11)
Granada : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Granada : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Las Palmas de Gran Canaria : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Madrid : (606) Hospital Universitario La Paz
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Madrid : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Majadhonda : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Malaga : (603) Hospital Clinico Universitario Virgen de la Victoria
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Palma de Mallorca : (602) Hospital Son Llatzer
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Pontevedra : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Sabadell : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Salamanca : (605) Hospital Universitario de Salamanca, Hospital Clinico, Sevicio de Hematologia
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Salamanca : Novartis Investigative Site
Efficacy and Safety of Deferasirox in Patients With Chronic Anemia and Transfusional Hemosiderosis
Santander : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Santiago de Compostela : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Sevilla : (608) Hospital Universitario Virgen del Rocio
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Terrassa : Hospital Mutua de Terrassa
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO 11)
Valencia : (601) Hospital La Fe, Servicio de Hematologia
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Valencia : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Valencia : Novartis Investigative Site
Efficacy and Safety of Deferasirox in Patients With Chronic Anemia and Transfusional Hemosiderosis
Valencia : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Xativa : Hospital Lluis Alcanyis
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO 11)
Sweden
Falun : Kvinnokliniken, Falu lasarett
Comparative Efficacy and Safety of Intravenous Ferric Carboxymaltose (FCM) Versus Oral Iron for Iron Deficiency Anaemia in Pregnant Women
Göteborg : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Linkoping : Linkopings Universitetssjukhus
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO 11)
Lund : Kvinnokliniken, University Hospital
Comparative Efficacy and Safety of Intravenous Ferric Carboxymaltose (FCM) Versus Oral Iron for Iron Deficiency Anaemia in Pregnant Women
Mölndal : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
View More »
Malmö : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Stockholm : Kvinnokliniken, Karolinska University Hospital
Comparative Efficacy and Safety of Intravenous Ferric Carboxymaltose (FCM) Versus Oral Iron for Iron Deficiency Anaemia in Pregnant Women
Stockholm : Karolinska Universitetssjukhuset Huddinge, Centrum för fostermedicin KK
Comparative Efficacy and Safety of Intravenous Ferric Carboxymaltose (FCM) Versus Oral Iron for Iron Deficiency Anaemia in Pregnant Women
Stockholm : Karolinska University Hospital
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO 11)
Sundsvall : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Umeå : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Uppsala : University Hospital, Dept of obstetrics and gynecology Uppsala
Comparative Efficacy and Safety of Intravenous Ferric Carboxymaltose (FCM) Versus Oral Iron for Iron Deficiency Anaemia in Pregnant Women
Uppsala : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Switzerland
Aarau : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Basel : Universitätsspital Basel, Geburtshilfe und Schwangerschaftsmedizin Frauenklinik
Comparative Efficacy and Safety of Intravenous Ferric Carboxymaltose (FCM) Versus Oral Iron for Iron Deficiency Anaemia in Pregnant Women
Bern : Humboldtstrasse
Comparative Efficacy and Safety of Intravenous Ferric Carboxymaltose (FCM) Versus Oral Iron for Iron Deficiency Anaemia in Pregnant Women
Bern : Inselspital, Department of Obstetrics and Gynecology
Comparative Efficacy and Safety of Intravenous Ferric Carboxymaltose (FCM) Versus Oral Iron for Iron Deficiency Anaemia in Pregnant Women
Genève : HUG, Département de Gynécologie-Obstétrique
Comparative Efficacy and Safety of Intravenous Ferric Carboxymaltose (FCM) Versus Oral Iron for Iron Deficiency Anaemia in Pregnant Women
View More »
Lausanne : CHUV, Département de Gynécologie-Obstétrique
Comparative Efficacy and Safety of Intravenous Ferric Carboxymaltose (FCM) Versus Oral Iron for Iron Deficiency Anaemia in Pregnant Women
Lugano : OR Lugano, sede Ospedale Civico, Clinica ginecologia ostetricia
Comparative Efficacy and Safety of Intravenous Ferric Carboxymaltose (FCM) Versus Oral Iron for Iron Deficiency Anaemia in Pregnant Women
Sursee : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Zurich : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Zurich : Universitätsspital Zürich
Intravenous Ferric Carboxymaltose (Ferinject®) With or Without Erythropoietin in Patients Undergoing Orthopaedic Surgery
Zürich : Universitätsspital Zürich, Departement Frauenheilkunde
Comparative Efficacy and Safety of Intravenous Ferric Carboxymaltose (FCM) Versus Oral Iron for Iron Deficiency Anaemia in Pregnant Women
Taiwan
Changhua : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Kaohsiung : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Taichung : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Taichung City : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Tainan : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Thailand
Bangkok :
A Study of Intravenous Mircera for the Treatment of Anemia in Pediatric Patients on Hemodialysis.
Turkey
Adana : Cukurova University Hospital
Comparative Efficacy and Safety of Intravenous Ferric Carboxymaltose (FCM) Versus Oral Iron for Iron Deficiency Anaemia in Pregnant Women
Adana : Novartis Investigative Site
Efficacy and Safety of Deferasirox in Patients With Chronic Anemia and Transfusional Hemosiderosis
Ankara : (654) Gazi Universitesi Tip Fakultesi
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Ankara : Novartis Investigative Site
Efficacy and Safety of Deferasirox in Patients With Chronic Anemia and Transfusional Hemosiderosis
Istanbul : (652) Istanbul Universitesi Istanbul Tip Fakultesi
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
View More »
Istanbul : Zeynep Kamil Hospital, Arakiyeci Haci Mehmet Mahallesi.
Comparative Efficacy and Safety of Intravenous Ferric Carboxymaltose (FCM) Versus Oral Iron for Iron Deficiency Anaemia in Pregnant Women
Istanbul : Istanbul Uni. Ist. Med. Faculty
Comparative Efficacy and Safety of Intravenous Ferric Carboxymaltose (FCM) Versus Oral Iron for Iron Deficiency Anaemia in Pregnant Women
Istanbul : Novartis Investigative Site
Efficacy and Safety of Deferasirox in Patients With Chronic Anemia and Transfusional Hemosiderosis
Izmir : (653) Dokuz Eylul Universitesi Tip Fakultesi
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Izmir : Novartis Investigative Site
Efficacy and Safety of Deferasirox in Patients With Chronic Anemia and Transfusional Hemosiderosis
Ukraine
Chernivtsi : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Dnipropetrovsk : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Kirovograd : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Kyiv : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Lutsk : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
View More »
Lviv : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Sumy : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Uzhgorod : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
United Kingdom
Birmingham : Research Site
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease
Bournemouth : (707) Royal Bournemouth Hospital
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Bradford : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Cardiff : (706) University Hospital of Wales
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Cardiff : Cardiff University
Accuracy Testing of the Chromosomal Aberration and Gene Mutation Markers of the AMLProfiler
View More »
Cottingham : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Coventry : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Derby : Research Facility
Efficacy and Safety of Peginesatide in the Treatment of Anemia in Patients With Chronic Kidney Disease
Dorechester : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Dorset : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Glasgow : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Harrow : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Kirkcaldy : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Leeds : (704) Saint James' University Hospital
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Leeds : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Leeds : Research Site
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease
Leicester : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Liverpool : Research Site
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
London : (702) King's College Hospital
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
London :
Combined Single / Multiple Dose Escalation Study in Patients With Renal Anemia Due to CKD (Chronic Kidney Disease)
London : Research Facility
Efficacy and Safety of Peginesatide in the Treatment of Anemia in Patients With Chronic Kidney Disease
London :
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO 11)
London : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
London : Guy's Hospital
Safety Study of MP4CO in Adult Sickle Cell Patients
London : King's College London
Safety Study of MP4CO in Adult Sickle Cell Patients
London : Research Site
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease
Manchester : (701) Christie Hospital
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Oxford : (705) John Radcliffe Hospital
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q
Romford : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Worthing : Worthing Hospital
Safety and Efficacy Study of Oral Ferric Iron To Treat Iron Deficiency Anaemia in Quiescent Crohn's Disease (AEGIS-2)
Worthing : Worthing Hospital
Safety and Efficacy Study of Oral Ferric Iron To Treat Iron Deficiency Anaemia in Quiescent Ulcerative Colitis (AEGIS-1)
York : Research Site
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
